Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2015

View Archived Issues

Genomes-to-Natural Products platform identifies small-molecule bacterial metabolites

Southern Research Institute divulges HGF and MSP maturation inhibitors

University of Pennsylvania Treatment Research Center to begin phase II study of NS-2359

Eagle Pharmaceuticals reports phase II results for dantrolene in exertional heat stroke

VEGFR/FGFR kinase inhibitor sulfatinib enters phase III in neuroendocrine tumors

Ligand to acquire Open Monoclonal Technology

Cortex Pharmaceuticals changes name and provides pipeline update

Janssen and Bavarian Nordic to develop prime-boost vaccine for HPV

Oslo Universitetssykehus divulges SERCA2-PDE3A interaction inhibitors

Astellas Pharma and Kotobuki Pharmaceutical present IRAP and P-LAP inhibitors

CSL Behring seeks Japanese approval of long-acting recombinant FIX-albumin fusion protein

Ionis Pharmaceuticals is new name for Isis Pharmaceuticals

Saronic files IND for phase I/II trial of SBI-1997 for hepatocellular carcinoma

Brickell Biotech reports data from phase IIb BBI-4000 trial in hyperhidrosis

Alnylam files CTA for ALN-GO1 for the treatment of primary hyperoxaluria type 1

Veltassa now available in the U.S. for the treatment of hyperkalemia

CHMP recommends approval of Lilly's necitumumab and ramucirumab

Genmab confirms agreement to transfer remaining ofatumumab rights

Luminex receives FDA clearance for NxTAG respiratory pathogen panel

E-selectin antagonist GMI-1271 advances to study in leukemia patients

Acid ceramidase inhibitor ARN-14988 shows synergy with cytotoxic drugs against melanoma cells

Neuralstem reports data from phase Ib trial of NSI-189 in patients with MDD

Artefenomel clears Plasmodium infection in phase II trial

Avisa Pharma's breath test detects tuberculosis in pilot trial

FDA approves Uptravi for pulmonary arterial hypertension

OLIG2 pathway inhibitors show promise for the treatment of glioblastoma

Mallinckrodt to acquire The Medicines Company's hemostasis portfolio

Bristol-Myers Squibb discloses IDO inhibitors

EMA committee supports approval of Shield's Feraccru to treat iron deficiency anemia

EMA CHMP recommends approval of Sanofi Pasteur MSD's hexavalent vaccine Vaxelis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...